Harrison Nicole, Grabmeier-Pfistershammer Katharina, Graf Alexandra, Schwarzinger Ilse, Aberle Judith H, Stiasny Karin, Greinix Hildegard, Rabitsch Werner, Kalhs Peter, Ramharter Michael, Burgmann Heinz, Forstner Christina
Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Division of Clinical and Experimental Immunology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
NPJ Vaccines. 2020 Jul 24;5(1):67. doi: 10.1038/s41541-020-00215-1. eCollection 2020.
The aim of this prospective study was to characterize the humoral immune response to TBE vaccination after hematopoietic stem cell transplantation (HSCT). Nineteen adult patients 11-13 months after HSCT and 15 age-matched immunocompetent adults received up to three TBE vaccinations. Antibodies against TBE virus were measured by neutralization test (NT). As primary endpoint, the antibody response (NT titer of ≥10 and at least a twofold increase from baseline 4 weeks after second vaccination) was compared between patients and controls using Fisher exact test. Prior vaccination, 15 (79%) HSCT patients still had detectable neutralizing antibodies. At primary endpoint, the antibody response was significantly lower in patients than in controls (35% versus 93%; < 0.001). The CD4+ cell count was a predictor for an antibody response in patients ( = 0.019). Interestingly, the majority of HSCT patients still had detectable antibodies prior vaccination. Following vaccination, antibody response in HSCT patients was associated with the CD4+ cell count.
这项前瞻性研究的目的是描述造血干细胞移植（HSCT）后对蜱传脑炎（TBE）疫苗接种的体液免疫反应。19例HSCT术后11 - 13个月的成年患者和15例年龄匹配的免疫功能正常的成年人接受了多达三次TBE疫苗接种。通过中和试验（NT）检测针对TBE病毒的抗体。作为主要终点，使用Fisher精确检验比较患者和对照组之间的抗体反应（第二次接种后4周NT滴度≥10且较基线至少增加两倍）。在接种疫苗前，15例（79%）HSCT患者仍可检测到中和抗体。在主要终点时，患者的抗体反应明显低于对照组（35%对93%；P<0.001）。CD4 +细胞计数是患者抗体反应的一个预测指标（P = 0.019）。有趣的是，大多数HSCT患者在接种疫苗前仍可检测到抗体。接种疫苗后，HSCT患者的抗体反应与CD4 +细胞计数相关。
